In the following video, Motley Fool health-care analyst David Williamson brings investors up to speed on the patent battle between Gilead and Idenix over the next generation of drugs to treat hepatitis C, one of the hottest spaces in health care today based on some incredible recent successes. David tells investors how Gilead may have won this particular round of the battle and what the war could mean for both companies down the road.
While you can certainly make huge gains in biotech and pharmaceuticals, the best investing approach is to choose great companies and stick with them for the long term. The Motley Fool's free report "3 Stocks That Will Help You Retire Rich" names stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of. Click here now to keep reading.
The article 2 Biotechs' Critical Patent Showdown originally appeared on Fool.com.
David Williamson has no position in any stocks mentioned. The Motley Fool recommends and owns shares of Johnson & Johnson. It also recommends Gilead Sciences. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.